|Bid||2.85 x 500|
|Ask||2.87 x 200|
|Day's Range||2.53 - 2.87|
|52 Week Range||0.50 - 4.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.67|
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
AVEO Oncology today reported financial results for the full year ended December 31, 2017 and provided a business update.
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m.
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / U.S. markets spiked to session highs after minutes from the Fed's January meeting were released, but then dropped as yields for the 10-year Treasury note ...
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Stock Monitor: Bio-Techne Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on AVEO Pharma, Inc. (NASDAQ: AVEO ). If you ...
AVEO Oncology today announced that the United Kingdom’s National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA® for the first line treatment of adult patients with advanced renal cell carcinoma .
AVEO Oncology and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral tivozanib in combination with intravenous nivolumab , an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma .
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
AVEO Oncology today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly & Company, ImClone Systems, Dendreon ...
Michael Bailey took the helm as AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO and grew market cap to $363.25M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
LONDON, UK / ACCESSWIRE / January 23, 2018 / Active-Investors.com has just released a free research report on AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) ("AVEO"). If you want access to this report ...
AVEO Oncology today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® , a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor receptors, in patients with advanced, unresectable hepatocellular carcinoma .
NEW YORK, NY / ACCESSWIRE / January 17, 2017 / Early gains from the major indexes were erased Tuesday as political concerns weighed down the market's recent rally. The Dow Jones Industrial Average declined ...
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is wrapping up the refinancing of its existing debt facility with Hercules and affiliates: one with a $20 million tag. The terms of the refinancing will provide a roughly $12.1 million in cash flow over the course of this year and next when against the previous loan, and the AVEO corporate team is rejoicing that this will extend the runway into 2019. Proceeds of the new facility will be used to retire the Company’s existing $20.0 million of secured debt with Hercules.
AVEO Oncology today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its affiliates, the terms of which enable approximately an additional $12.1 million in cash flow over 2018 and 2019, when compared to the prior loan.
Investors in AVEO Pharmaceuticals (AVEO) need to pay close attention to the stock based on moves in the options market lately.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced updates on clinical development for FOTIVDA® (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway. Enrollment Complete in Phase 2 Portion of Phase 1/2 TiNivo Trial in Advanced RCC. AVEO announced today that enrollment of 21 patients is now complete, with one patient remaining in screening, in the Phase 2 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb’s OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced RCC.
AVEO Oncology today announced clinical updates for two of its oncology programs: FOTIVDA® , the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the hepatocyte growth factor ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met ...
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today expanded its executive team by naming Nikhil Mehta, Ph.D. as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience in the biotechnology and pharmaceutical industries, having played a key role in the development and approval of important therapeutic products in the areas of oncology and orphan disease.